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Apoptosis signal-regulating kinase 1 (ASK1)
plays an essential role in stress and immune re-
sponse and has been linked to the development
of several diseases. Here, we present the struc-
ture of the human ASK1 catalytic domain in
complex with staurosporine. Analytical ultra-
centrifugation (AUC) and crystallographic anal-
ysis showed that ASK1 forms a tight dimer (Kd
 0.2 mM) interacting in a head-to-tail fashion.
We found that the ASK1 phosphorylation
motifs differ from known ASK1 phosphorylation
sites but correspond well to autophosphoryla-
tion sites identified by mass spectrometry.
Reporter gene assays showed that all three
identified in vitro autophosphorylation sites
(Thr813, Thr838, Thr842) regulate ASK1 signal-
ing, but site-directed mutants showed catalytic
activities similar to wild-type ASK1, suggesting
a regulatory mechanism independent of ASK1
kinase activity. The determined high-resolution
structure of ASK1 and identified ATP mimetic
inhibitors will provide a first starting point for
the further development of selective inhibitors.
INTRODUCTION
Apoptosis signal-regulating kinase 1 (ASK1, also called
MAP3K5) is a mitogen-activated protein kinase kinase
kinase (MAP3K) that plays an essential role in cellular
stress and the immune response (Matsukawa et al.,
2004). ASK1 activates both the JNK and p38 pathways
by direct phosphorylation of MAP kinase kinases
(MKKs). ASK1 is activated by various stimuli, including
lipopolysaccharide (LPS), oxidative stress (ROS), endo-
plasmatic reticulum (ER) stress, influx of calcium ions,
cytokines (such as tumor necrosis factor a), Fas ligand,
and GPCR agonists (Ichijo et al., 1997; Chen et al., 1999;
McDonald et al., 2000). ASK1 knockout mice (ASK1/)
show no overt macroscopic or microscopic phenotype
but are resistant to LPS-induced septic shock, demon-Structure 15, 1215–12strating the essential role of ASK1 in inflammatory signal-
ing (Matsuzawa et al., 2005). Overexpression of ASK1 can
induce apoptosis but depending on the cellular context
may also promote differentiation and survival (Takizawa
et al., 2002; Sayama et al., 2001).
ASK1 has been linked to several diseases and has been
discussed as a target for pharmaceutical intervention
(Hashimoto et al., 2003; Harada et al., 2006). For example,
ASK1 has been implicated in polyglutamine (PolyQ) dis-
eases, which include at least nine inherited neurodegen-
erative disorders: Huntington’s disease (HD), spinobulbar
muscular atrophy (SBMA), dentatorubral-pallidoluysian
atrophy (DRPLA), six spinocerebellar ataxias, and SCA3/
Machado-Joseph disease (MJD). During disease progres-
sion, polypeptides called PolyQ fragments accumulate as
aggregates in the cytoplasm and/or nucleus and induce
cellular stress that leads to neuronal cell death in an
ASK1-dependent manner (Kariya et al., 2005; Nishitoh
et al., 2002; Sekine et al., 2006). ASK1 is also a potential
therapeutic target for treating malignant fibrous histiocy-
tomas, a particularly aggressive form of undifferentiated
liposarcoma (Chibon et al., 2004). Activation of ASK1 by
reactive oxygen species is also a key mechanism for
b-amyloid induced neurotoxicity in Alzheimer’s disease
(Hashimoto et al., 2003; Kadowaki et al., 2005; Song
et al., 2003).
Human ASK1 is a polypeptide of 1,374 residues con-
sisting of a central serine/threonine kinase domain and
coiled-coil domains in both the N and C termini (Figure 1).
ASK1 interacts with a large number of partners, form-
ing a high molecular weight complex of approximately
1,500–2,000 kDa designated the ASK1 signalosome
(Tobiume et al., 2002; Noguchi et al., 2005). In its rest-
ing state, ASK1 forms a homodimer stabilized by the C-
terminal coiled-coil domain. The N-terminal domain is
bound to the redox-regulatory protein thioredoxin (TRX),
preventing its activation. Oxidative stress leads to disul-
fide bridge formation in TRX and dissociation from
ASK1 (Saitoh et al., 1998; Liu and Min, 2002; Zhang
et al., 2004). This triggers a conformational change in
the ASK1 dimer leading to phosphorylation at the activa-
tion segment residue Thr838 by either autophosphoryla-
tion or transphosphorylation by an unidentified kinase
(Tobiume et al., 2002).26, October 2007 ª2007 Elsevier Ltd All rights reserved 1215
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Structure of ASK1Figure 1. Overall Structures of ASK1 and Sequence Comparison to PAK1
(A) Domain architecture of ASK1. Coiled-coil domains are shown in blue, the kinase domain in red, and the 14-3-3 binding site in green. Predicted
domain boundaries (residues) are given in the numbers above the sketch.
(B) Ribbon diagram showing a structural overview. Secondary structure elements were determined with the program ICMPro 3.4-8 (Molsoft, LLC) and
have been labeled according to the nomenclature established for PKA (Knighton et al., 1991a). The helices are shown in red, b strands in green, and
the 310-helices in magenta. Disordered regions are indicated by dotted lines, and location of autophosphorylation sites are indicated by a yellow ‘‘P.’’
(C) Superimposition of ASK1 (red) with its closes structural neighbor PAK1 (yellow).
(D) Structure-based sequence alignment of ASK1 with PAK1. Secondary structure elements of ASK1 are also shown and labeled. Autophosphory-
lation sites identified by mass spectrometry are indicated by ‘‘P.’’ Residues not included in the model due to disorder are indicated by lower case
letters.Activated ASK1 directly phosphorylates MKK3/MKK6
and MKK4/MKK7, resulting in activation of the p38 and
JNK MAPKs, respectively. A consensus docking site of
24 amino acids, called the DVD domain, is located in the
C terminus of MKKs and has been proposed to interact1216 Structure 15, 1215–1226, October 2007 ª2007 Elsevier Ltdwith the kinase domain of ASK1, thus promoting the spe-
cific targeting of these downstream kinases (Takekawa
et al., 2005).
Here, we present the high-resolution structure of the
kinase domain of ASK1 in complex with the genericAll rights reserved
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Structure of ASK1Table 1. Data Collection and Refinement Statistics
Native Selenomethionine
Space group P6522 P41212
Cell (A˚) a = b = 78.16; c = 423.28 a = b = 92.58; c = 85.19
Number of reflections 536667 116678
Number of unique data 35817 8659
Resolution (A˚)a 47.0–2.30 (2.4–2.3) 46.3–2.90 (3.0–2.9)
Completenessa 99.3% (93.9%) 99.6% (96.7%)
I/s(I)a 17.7 (1.9) 19.5 (2.8)
Rint
a 0.0991 (0.5924) 0.1047 (0.6648)
Rwork/Rfree 0.204/0.257 -
Rmsd bond
length (A˚)
0.014 -
Rmsd bond angle 1.52 -
B-factors (overall) (mainchain, sidechain, solvent) 38.5 (38.4, 39.8, 33.6) -
Ramachandran Most favored: 91.6%; additionally allowed:
8.2%; generously allowed: 0.2%; disallowed: 0%
aValues in brackets indicate values in the highest resolution shell.protein kinase inhibitor staurosporine. We show that the
ASK1 catalytic domain is dimeric in solution and that it is
an active kinase in its unphosphorylated state. We identi-
fied a consensus recognition sequence for ASK1 by pep-
tide library screening that is in agreement with in vitro
autophosphorylation sites identified by mass spectrome-
try. The high-resolution crystal structure together with
the in vitro characterization of this enzyme provide a basis
for the further understanding of ASK1 regulation and for
the development of specific inhibitors for this interesting
target.
RESULTS
Overall Architecture
The ASK1 catalytic domain structure displays a typical
protein kinase fold comprising the five b sheets and helix
aC constituting the small lobe (residues 670–757) and
a larger mainly alpha helical C-terminal lobe (residues
761–940) (Figure 1). The hinge region connecting the two
domains lines the catalytic ATP binding site, which is oc-
cupied by the ATP competitive inhibitor staurosporine.
The asymmetric unit harbors two ASK1 molecules, which
can be superimposed with an rmsd of 0.6 A˚ and can there-
fore be considered structurally identical. Residues located
in the loop regions at the beginning of aC (Asp715-Ser719)
and the activation segment residues Gly831-Glu837 were
not visible in the electron density and were assumed to be
disordered. The N-terminus forms a short b sheet (b0),
which is connected to the sheet b1 by an unusually large
loop comprising residues 675–684. This large loop inser-
tionmay play a role in regulation of ATP binding since it de-
termines the position of the phosphate binding loop,Structure 15, 1215whereas the N-terminal sheet b0 extends the antiparallel
sheet network in the smaller lobe, possibly adding stability
to this domain.
ASK1 is only distantly related in sequence to kinases
of known structure. Superimposition with the catalytic
domain of its next structural neighbor PAK1 (PDB code:
1YHW; 29% sequence identity) revealed that the two
kinases superimposewith an rmsdof about 2 A˚ (Figure 1C).
However, structure determination by molecular replace-
ment was challenging and required an improved search
model built on the basis of SAD data collected from
another crystal form (Table 1). Themost striking difference
between these two structures is that helix aC in ASK1 is
moved further away from the active site. This has also
been described for the MAP3K family member and the
closest relative on the phylogenetic tree, TAK1 (PDB
code: 2EVA). As a consequence of the outward shifted
aChelix, the hydrogenbondbetween theconserved active
site lysine (Lys709) and aC glutamate (Glu725) typically
found in active kinases is not present in the ASK1 structure
described here, and the domain therefore assumes a
catalytically nonproductive conformation.
Active Site and Binding of Staurosporine
Staurosporine binds to the ATP binding site of ASK1 in
a mode that has been described for a number of kinase-
staurosporine complexes (Underwood et al., 2003; Ber-
trand et al., 2003) (Figure 2). Two hydrogen bonds anchor
the lactam moiety to the hinge region and mimic the
hydrogen-bonding pattern of the adenine base. The staur-
oporine ligand forms a third hydrogen bond with the back-
bone oxygen of the catalytic loop residue Asn808, an
interaction that has been described previously (Lamers
et al., 1999; Lawrie et al., 1997; Prade et al., 1997; Zhao–1226, October 2007 ª2007 Elsevier Ltd All rights reserved 1217
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Structure of ASK1et al., 2002; Zhu et al., 1999). The heterocyclic condensed
five-ring system packs against the hydrophobic side
chains of the ASK1 residues Leu686, Val694, and Ala707
on the N-terminal lobe side as well as Val738 and
Leu810 on the C-terminal lobe side of the binding pocket.
In addition to staurosporine, we identified a number of
diverse inhibitors in the melting temperature screen per-
formed on a library of 158 known kinase inhibitors (Table
S1 and Figure S1 in the Supplemental Data available
with this article online). The inhibitors have been used in
cocrystallization experiments, but well-diffracting crystals
were only obtained in the presence of staurosporine.
Activation Segment
Although not phosphorylated, the activation segment was
well defined by electron density except for the unstruc-
tured tip of the activation loop (residues 832–836). Inter-
estingly, the conserved aC glutamate (Glu725) forms a
hydrogen bond with the main-chain nitrogen of the DFG
motif residue Phe823, whereas the conserved active site
lysine (Lys709), which usually forms a salt bridge with
the aC glutamate in active kinases, also hydrogen bonds
to the main chain of Phe823 (Figure 3A). The DFG aspar-
tate (Asp822) forms a hydrogen bond with the activation
segment residue Ser826. The observed noncatalytic con-
formation might be influenced by the presence of the
bulky ATP competitive ligand staurosporine, which forms
hydrophobic contacts with the DFG Phe823. In contrast,
C-terminal to the DFG motif the activation segment is sta-
bilized by interactions typically found in activated kinases.
Comparison with the structure of phosphorylated, active
PAK4 (Eswaran et al., 2007) revealed that the ASK1 activa-
tion segment residue Glu837 mimics the hydrogen-bond
pattern formed by an activating phosphate moiety. In ac-
tive kinases, phosphorylation at this position typically re-
sults in formation of a hydrogen bond network linking
the catalytic loop arginine of the HRD motif (Arg802 in
ASK1) with both termini of the activation segment (Lawrie
Figure 2. Binding of Stauroporine
Main interacting active site residues with the ATP competitive inhibitor
staurosporine are shown in ball-and-stick representation. Hydrogen
bonds formed between the ligand and the protein are shown as dotted
lines.1218 Structure 15, 1215–1226, October 2007 ª2007 Elsevier Let al., 1997). These interactions stabilize the activation
segment in a conformation competent for substrate bind-
ing (Figures 3B and 3C). Activation segment mutants that
lead to activation of kinases such as the S474E mutant in
Figure 3. Activation Segment of ASK1
(A) Interaction between the helix aC and the DFG motif. Hydrogen
bonds are shown as dotted lines.
(B) Hydrogen bond network stabilizing N- and C-terminal portion of the
activation segment and link the ASK1 activation segment to the cata-
lytic loop residue Arg802.
(C) Interaction stabilizing the activation segment in the active and
phosphorylated kinase PAK4 (Eswaran et al., 2007).td All rights reserved
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Structure of ASK1Figure 4. Dimerization of ASK1 Kinase Domain
(A) Sedimentation velocity and equilibrium results of ASK1. Sedimentation velocity plot of the differential sedimentation coefficient distribution, c(s),
versus the apparent sedimentation coefficient corrected to water at 20C, s20,w of ASK1, together with the differential molecular weight distribution,
c(M), versus molecular weight, M. Experiments were conducted with a protein concentration of 13 mM. Shown are Tri-phosphorylated ASK1 (red line),
mixture of un- and monophosphorylated ASK1 (black line), and the mutant Thr813Ala (blue).
(B) Sedimentation equilibrium experiment employing a rotor speed of 10,000 rpm. The solid line denotes a fitted curve resulting from global nonlinear
regression analysis with a self-association model. The residuals for the fit are shown in the upper panel of the graph. The determined dissociation
constant for the dimer was (KD) of 0.22 ± 0.2 mM.
(C) Dimer interface spanning almost the entire side of ASK1 kinase domain. Both molecules interact in a head-to-tail orientation.
(D) Details of interactions located in the dimer interface.PAK1 (Lei et al., 2005), or activation segments of constitu-
tively active wild-type kinases, mimic the hydrogen bond
patterns formed by the activating phosphate moiety.
Thus, the position and interactions formed by Glu837
in ASK1 suggest an activating and stabilizing function
of this residue in unphosphorylated ASK1. Indeed, we
observed that unphosphorylated ASK1 is active and auto-
phosphorylates rapidly at three sites in vitro.
ASK1 Catalytic Domain Dimerizes
with a Head-to-Tail Orientation
Full-length ASK1 has been described as a dimeric mole-
cule stabilized in vivo by coiled-coil domain located C-ter-
minal to the catalytic domain. Consequently, dimerization
of the kinase domain was not an anticipated finding. Anal-
ysis of crystal packing revealed that the two ASK1 mole-
cules in the asymmetric unit dimerize with their own sym-
metry equivalent. Both molecules bury a total surfaceStructure 15, 1215–1area of about 1,997 A˚2 consisting of 473 A˚2 of hydrophobic
and 1524 A˚2 of hydrophilic surface. In order to verify the
dimeric state of the ASK1 kinase domain in solution, we
carried out analytical ultracentrifugation experiments (Fig-
ure 4). Sedimentation velocity measurements led to the
determination of an apparent sedimentation coefficient
corrected for water at 20C, s020;w, of 4.518 S, as well as
the determination of a protein molecular weight of 66 kDa,
which is in excellent agreement with the expected mass
of an ASK1 catalytic domain dimer. Equilibrium experi-
ments performed at three concentrations (c0, c0/2, and
c0/4, where c0 is the concentration used in the velocity
experiment) confirmed a stable dimeric state of the kinase
domain in solution (Figure 4B). Nonlinear least square fit to
a self association fitting model resulted in determination
of a dissociation constant (KD) of 0.22 ± 0.2 mM.
The interaction between ASK1 monomers is based pri-
marily on shape complementarity over a large surface226, October 2007 ª2007 Elsevier Ltd All rights reserved 1219
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Structure of ASK1Figure 5. Substrate Specificity of ASK1 and Identification of
Autophosphorylation Sites
(A) Phosphorylation motifs for ASK1. Biotinylated peptides bearing the
indicated residue at the indicated position relative to a central Ser/Thr
phosphoacceptor site were subjected to phosphorylation by ASK1
with radiolabeled ATP. Aliquots of each reaction were subsequently
spotted onto a streptavidin membrane, which was washed, dried,
and exposed to a phosphor screen. Shown is a representative array
from three separate experiments. Quantified spot intensities repre-
senting the average of the three runs are provided in Table S2.
(B) Consensus sequence determined from the peptide array data. The
consensus sequence is shown in bold and alternative residues are
indicated at each position by smaller italic letters. The site of phos-
phorylation is indicated in red and by a star (*). The three autophos-
phorylation sites are also shown, and residues matching the consen-
sus sequence are highlighted with yellow boxes.
(C) Activation segments of the known ASK1 substrates of the MKK
family of kinases. Residues phosphorylated by activation are high-
lighted in red.1220 Structure 15, 1215–1226, October 2007 ª2007 Elsevier Larea spanning almost the entire length of the protein. To
achieve such a tight interaction, the molecules associate
in a head-to-tail fashion with the N-terminal domain of
one molecule interacting with the C-terminal domain of
the other molecule and vice versa. The two catalytic sites
are on the same side of the dimer near the equatorial plane
and around 20 A˚ apart. Interaction between the molecules
involves a number of direct hydrogen bonds (Leu700-
Asn776’, Asn702-Tyr783’, Gln703-Thr779’, and Arg705-
Thr813’ [and vice versa]), as well as water-mediated
hydrogen bonds (Gln756-HOH-Tyr814’) (the apostrophe
denotes the symmetry equivalent molecule). In addition,
multilayer p-stacking and hydrophobic interactions
Arg705-Tyr814’-Pro758/Pro758’-Tyr814-Arg705’ may also
contribute todimerization (Figures4Cand4DandTableS3).
One of the identified phosphorylation sites (Thr813) is
located in the dimer interface, and phosphorylation at
this residue is likely to result in formation of hydrogen
bonds to Arg705 located in the interacting protomer. We
were therefore interested to explore if phosphorylation
at Thr813 effects dimerization of ASK1. However, AUC
data indicated that dephosphorylated ASK1 (mixture
between de- and monophosphorylated ASK1) homoge-
neously triphosphorylated ASK1 as well as a T813A mu-
tant formed all stable dimers in solution, and sedimenta-
tion equilibrium experiments revealed similar association
behavior (Figure 4).
Sequence Specificity of the ASK1 Substrate
Binding Site
In order to determine the sequence specificity of active
site-mediated phosphorylation, we screened a peptide
library with recombinant ASK1 (Figure 5A). The library
was constructed to evaluate the contribution of all amino
acid residues at each of nine positions (5 to +4) sur-
rounding a fixed central phosphoacceptor site (Hutti
et al., 2004). The phosphorylation data revealed that
ASK1 has a substantial preference for threonine over ser-
ine as a phospho-acceptor. ASK1 appears to be most
selective at position +1 relative to the phosphorylation
site, where it strongly prefers both aromatic and aliphatic
hydrophobic residues in peptide substrates. We also
observed strong phosphorylation of peptides bearing
threonine residues in either the 2 or the +2 position. Be-
cause peptides in the library with fixed threonine residues
can theoretically be phosphorylated at more than one site,
these signals could reflect authentic selection for threo-
nine at only one of the two positions. ASK1 also has sec-
ondary preferences for glutamine at the 2 position and
for serine, arginine, and tyrosine at the +2 position. The
kinase is not strongly selective at any of the other positions
represented in the peptide library. The determined con-
sensus motif is shown in Figure 5B.
(D) Location of the three autophosphorylation sites in ASK1. Phosphor-
ylated residues are labeled in red and are shown as spheres, whereas
neighboring residues are labeled in blue and are indicated in ball-and-
stick representation. The interacting ASK1 dimer is shown in green.td All rights reserved
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Structure of ASK1Autophosphorylation Sites of ASK1
The mass spectrum of the intact recombinant protein
treated with ATP/Mg2+ clearly indicated the presence of
at least three phosphorylation sites (Figure S2). The pro-
tein used for crystallization also contained small amounts
of the monophosphorylated species arising during ex-
pression of the protein. The electron density map showed
that Thr838 is partially phosphorylated, but due to the low
occupancy of the phosphate moiety at this site, the phos-
phothreonine could not be convincingly modeled. An
autophosphorylation site was identified on Thr813, which
is located in the loop region connecting the sheets b8 and
b9 pointing toward the C terminus of helix aD. The site is
located at the protein surface very distant from the cofac-
tor or substrate binding sites, but phosphorylation at
Thr813 could impact lobe dynamics and thereby indirectly
influence catalysis. Thr813 is also located in the dimer
interface in close proximity to Arg705 of the interacting
catalytic domain located in the loop between b2 and b3,
Figure 6. Effects of Mutation at T813A, T838A, and T842A on
ASK1 Activity
(A) 293T cells were transfected with various ASK1 mutants in the pres-
ence of an ASK1-JNK-dependent reporter gene. A renilla construct
was cotransfected as an internal control. HIPK1-WT and T838A were
used as controls. Both luciferase and renilla units were measured. Rel-
ative luciferase activities are presented from mean of duplicate sam-
ples by taking vector control as 1. Similar results were obtained from
two additional experiments. Data are presented as mean of duplicates
from two independent experiments. ASK1 protein expression was de-
termined by Western blot (lower panel) with anti-HA-POD (anti-HA-
conjugated peroxidase; Roche).
(B) The ASK signaling pathway was reconstituted in vitro with recombi-
nant ASK1 and its phosphorylation site mutants, MKK6 as well as p38.
p38 phosphorylation was detected with an antibody specific phos-
phorylated p38. Corresponding Coomassie gels as well as a his-tag-
specific antibody has been used to demonstrate identical loading con-
centrations of the samples.Structure 15, 1215–12but significant effects on dimerization were ruled out by
AUC experiments carried out on an alanine mutant. In
dimeric ASK1, Thr813 is not accessible, and the dissocia-
tion constant determined for the dimer association sug-
gests that phosphorylation at this site is a slow process.
However, structural changes in the ASK1 signalosome,
which are likely to occur upon activation, might render
this site more accessible.
A second site was identified at Thr838, which is located
in the activation segment. In our structure, the side chain
of Thr838 is oriented toward the solvent, and phosphory-
lation at this site is not expected to stabilize the activation
segment in the absence of structural rearrangements. Fur-
thermore, as described above, the neighboring residue
Glu837 forms interactions typically formed by a phosphate
moiety located at the corresponding position within the
activation segment. However, Thr838 has been shown
to play an essential role in activation of ASK1 by oxidative
stress (Tobiume et al., 2002). A third phosphorylation site
was identified at Thr842 located in close proximity (2.6 A˚)
to the catalytic aspertate (Asp803), and phosphorylation
at Thr842 may lead to formation of hydrogen bonds with
the catalytic loop lysine Lys805. All three sites, in partic-
ular Thr838, are in good accordance with our deter-
mined consensus peptide phosphorylation motif for
ASK1 (Figure 5B) in contrast to known phosphorylation
sites of downstream ASK1 substrates (Figure 5C). The
location of the three autophosphorylation sites in our
structural model is shown in Figure 5D.
Role of ASK1 Catalytic Domain
Phosphorylation Sites
To study the role of each of the identified autophosphory-
lation sites, we cloned site-directed alanine mutants into
an expression vector and studied the effects of the muta-
tions in transient transfection assays, monitoring JNK/p38
reporter gene activity. As expected from earlier studies,
mutation of Thr838 drastically reduced reporter gene
activity when compared to unstimulated control levels. In-
terestingly, mutation of the other two sites also provided
a significant reduction in ASK1 function (Figure 6A), sug-
gesting that autophosphorylation at the residues Thr842
and Thr813 regulates ASK1 signaling.
Furthermore, we studied the effect of the site-directed
alanine mutants on kinase catalytic activity in vitro. Re-
combinant ASK1 mutants autophosphorylated rapidly
and had specific activities that were comparable to wild-
type ASK1 (data not shown). To test if the generated
ASK1 mutants are also active on specific ASK1 sub-
strates, we reconstituted a minimal ASK1 signaling cas-
cade (ASK1-MKK6-p38) in vitro with recombinant MKK6
and His6-p38a by detecting p38 phosphorylation with an
antibody specific for phosphorylated p38. Surprisingly,
all three mutants showed catalytic activity in this in vitro
phosphorylation experiment comparable to wild-type
ASK1, suggesting that phosphorylation at the three cata-
lytic domain autophosphorylation sites may be required
for the recruitment of signaling partners and ASK126, October 2007 ª2007 Elsevier Ltd All rights reserved 1221
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Structure of ASK1substrates to this large signalosome rather than for regu-
lation of catalytic activity.
DISCUSSION
ASK1 shares only moderate sequence homology with the
catalytic domains of other human protein kinases. Apart
from its closely related isoform ASK2 (MAP3K6) the next
phylogenetic neighbors share sequence identities of only
about 50% with the ASK1 catalytic domain. As a conse-
quence, the structure of ASK1 determined in this study
represents a chemically diverse kinase catalytic domain.
Recombinant ASK1 was found to be catalytically active
and rapidly autophosphorylated at Thr813, Thr838, and
Thr842 in vitro. Even though recombinant ASK1 is catalyt-
ically active, the structure of ASK1 was found to assume
a catalytically not competent conformation as indicated
by the distal position of aC from the active site, the confor-
mation of the DFG motif that would not allow binding of
a metal ion and by the partial disorder of the activation
loop tip. Inactive conformations are quite frequently ob-
served in active kinases and reflect the dynamic nature
of the kinase catalytic domain (Eswaran et al., 2007).
Reporter gene assays of site-directed mutants demon-
strated that all three residues are important for ASK1 sig-
naling in cells. For mouse ASK1, corresponding activation
loop positions for Thr838 and Thr842 (Thr845 and Thr849)
have been identified earlier as critical residues for ASK1
activity by alanine scanning mutagenesis of all possible
activation loop phosphorylation sites (Tobiume et al.,
2002). In addition to these autophosphorylation sites,
phosphorylation of three Ser residues (Ser83, Ser967,
and Ser1034) by other kinases also regulate ASK1 signal-
ing activity (Zhang et al., 1999; Kim et al., 2001; Fujii et al.,
2004; Zhang et al., 2005) and the recruitment of binding
partners. The association of ASK1 with the two phospha-
tases PP5 and Cdc25A supports a pivotal role for phos-
phorylation in regulating ASK1 activity (Morita et al.,
2001; Zou et al., 2001).
Thr842 forms a hydrogen bond with the catalytic aspar-
tate residue, which is destroyed by mutating this residue
to alanine. However, the recombinant protein is still active
and phosphorylates specific substrates (e.g., MKK6) with
similar activity than wild-type ASK1. Interestingly, the
analogous position in the activation segment has also
been described as a regulatory phosphorylation site for
DAPK3 (Thr150) (Graves et al., 2005) and CHK2
(Thr387). Phosphorylation at this site has been shown to
be critical for CHK2 activity, and the mutation Thr387Ala
is unable to trigger the G1 checkpoint (Lee and Chung,
2001).
Surprisingly, the ASK1 activation loop conformation
does not explain how phosphorylation on Thr838 influ-
ences ASK1 activity, and interestingly, the mutant
Thr838Ala is catalytic active and recognizes both auto-
phosphorylation sites as well as specific substrates with
similar efficiency as wild-type ASK1 in vitro. Thus, it is
likely that in the absence of Thr838 phosphorylation, the
neighboring residue Glu837 mimics hydrogen bond pat-1222 Structure 15, 1215–1226, October 2007 ª2007 Elsevier Ltterns typically formed by an activating phosphate moiety
(Nolen et al., 2004). In the structure determined here, the
side chain of Thr838 is oriented toward the solvent sug-
gesting that formation of new stabilizing interactions
upon phosphorylation would require structural rearrange-
ment of the activation segment.
Such a conformational change is likely to contribute to
the peptide phosphorylation specificity that we observed
for ASK1. The serine-threonine kinases PKA and PKB/
Akt are phosphorylated at activation loop sites analogous
to that of ASK1 Thr838 and like ASK1, have a preference
for hydrophobic, particularly aromatic residues at the +1
position in their substrates. In these kinases, two residues
form a hydrophobic pocket that accommodates residues
found at the +1 position in substrates: the residue immedi-
ately upstream of the APE sequence that terminates the
activation loop (analogous to Met846 of ASK1) and the
residue immediately downstream of the phosphorylated
Thr within the loop (analogous to Phe839 of ASK1)
(Knighton et al., 1991b; Yang et al., 2002). In the present
structure, Phe839 is pointed toward the interior of the pro-
tein and is not in close contact with Met846, and thus no
+1 hydrophobic pocket is apparent. Formation of a hydro-
phobic site analogous to that found in PKA and PKB/Akt
would require a portion of the activation loop, including
Phe839, to rotate 120 relative to its position within the
structure. This rearrangement could be triggered through
phosphorylation of Thr383 and its consequent interaction
with Arg802.
In contrast to the autophosphorylation sites, which
closely match the determined consensus sequence,
several of the ASK1 phosphorylation sites on downstream
MKK substrates do not. Phosphorylation of these noncon-
sensus sites may be driven by complex formation be-
tween ASK1 and the MKKs, which could overcome a spe-
cific sequence requirement at the phosphorylation site.
Alternatively, structural changes in the activation segment
that may impact phosphorylation site selectivity could be
induced by binding of an ASK1 substrate to theDVDdock-
ing site. Significant rearrangement of the activation seg-
ment has recently been reported for the MAPK ERK2
upon engagement of a docking site (Zhou et al., 2006).
In MAPKs, D motif docking peptides bind at analogous
sites to p38a and JNK1 and induce conformational
changes unique to each kinase (Chang et al., 2002; Heo
et al., 2004). In ERK2, binding of the docking peptide re-
sults in a new conformation of the activation loop, while
in p38a and JNK1 docking interactions induce disorder
in the activation segment. Such allosteric effects associ-
ated with binding of docking peptides may provide a gen-
eral mechanism for increasing signal flux and specificity in
phosphorylation cascades, by inducing a conformation
that promotes phosphorylation by the upstream kinase.
This study revealed that the catalytic domain of ASK1
also dimerizes independently of C-terminal coiled-coil do-
mains. ASK1 has been reported to hetero-oligomerize
with the closely related protein ASK2 (MAP3K6) (Takeda
et al., 2007). All autophosphorylation sites as well as resi-
dues located in the dimer interface are conservedd All rights reserved
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heterodimers of ASK1 and ASK2 may also arrange in
a similar fashion. Moreover, ASK2 has been reported to
directly activate ASK1 by phosphorylation, suggesting
a mechanism of trans-activation within the ASK signalo-
some (Takeda et al., 2007). The head-to-tail orientation
of the ASK1 kinase domain shows homo or hetero
ASK1/2 oligomers aligned in a similar orientation as the
full-length proteins and imply that the kinase domain itself
makes an important contribution to formation of the dimer
in addition to the C-terminal coiled-coil domain. However,
more structural studies on complexes of ASK1with its sig-
naling partners and ideally the structure of full-length
ASK1 would be necessary to understand the molecular
details of the complex regulation of this kinase.
ASK1 has been suggested to be a potential target for
the treatment of polyglutamine (polyQ) diseases (Hashi-
moto et al., 2003; Harada et al., 2006) and is also a poten-
tial therapeutic target for malignant fibrous histiocytomas,
(Chibon et al., 2004). In addition, it has also been shown
that activation of ASK1 by ROS is a key mechanism for
amyloid b-induced neurotoxicity in Alzheimer’s disease
(Hashimoto et al., 2003; Kadowaki et al., 2005; Song
et al., 2003). Furthermore, ASK1 is an essential regulator
of innate immunity, and selective inhibitors would be inter-
esting reagents for the development of clinical anti-inflam-
matory agents to treat septic shock. The structures pre-
sented here as well as the inhibitors identified will enable
future structure-based development of selective inhibitors
for this kinase.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification
Human ASK1 (residues 659–951; gij5174547) was subcloned into the
T7 expression vector SGC-pLIC. The protein was expressed as an
N-terminally His6-tagged fusion protein with a tobacco etch virus
(TEV) protease cleavage site by using Escherichia coli BL21(DE3).
A 10 ml overnight culture was used to inoculate 1 l of Terrific Broth
media containing 100 mg/ml kanamycin. Cultures were grown at
37C until the OD600 reached 2.0. After that, the temperature was
adjusted to 25C, and expression was induced for 18 hr with 1 mM
IPTG. Cells were centrifuged and pellets were resuspended in binding
buffer (50mMHEPES [pH 7.5], 300mMNaCl, 20 mM imidazole includ-
ing a protease inhibitor cocktail [Complete, Roche]) and lysed with
a high-pressure homogenizer. The lysate was cleared by centrifuga-
tion, and the protein was purified by Ni-affinity chromatography with
a wash buffer (50 mM HEPES [pH 7.5], 1 M NaCl, 20 mM Imidazole)
and an elution buffer of the same composition but containing
250 mM imidazole. The eluted protein was treated with lambda and
alkaline phosphatase together with TEV protease for 12 hr at 4C to
remove phosphorylation and the His6-tag, respectively. The eluted
fraction was further purified by gel filtration chromatography with
Superdex S75 (60 3 1 cm) column equilibrated in 10 mM HEPES
(pH 7.5), 500 mM NaCl, 5% (w/v) glycerol. DTT was added to the pro-
tein sample to a final concentration of 10mM, and the protein was con-
centrated to 13 mg/ml. Purity and integrity of ASK1 were confirmed by
SDS/PAGE and electrospray ionization time-of-flight mass spectrom-
etry (Aglient LC-ESI TOF).
Analytical Ultracentrifugation
Sedimentation velocity experiments were carried out on a Beckman
XL-I Analytical Ultracentrifuge equipped with a Ti-50 rotor and cellsStructure 15, 1215–1with double-sector centerpieces. Protein samples were studied at
a concentration of 13 mM in 10 mM HEPES (pH 7.4) (at 25C),
120 mM NaCl, 0.25% glycerol at 4C, employing a rotor speed of
40,000 rpm. Radial absorbance scans were collected at a wavelength
of 280 nm in 1 min intervals. Data were analyzed with SEDFIT (Schuck,
2000) calculating c(s) distributions. The software package SEDNTERP
was used in order to normalize the obtained sedimentation coefficient
values to the corresponding values in water at 20C, s020;w, taking into
account the solvent density (ro= 1.00503 g/ml), viscosity (ho= 1.58623
102), and the protein partial specific volume (0.7309 ml/g). Sedimenta-
tion equilibrium experiments were performed with a six-sector center-
piece and protein concentrations of 6.5, 11.9, and 25.2 mM. Equilibrium
was obtained after 24 hr at each of the two centrifugation speeds
(10,000 rpm and 15,000 rpm). Baseline offsets were determined by us-
ing a meniscus depletion run. Sedimentation equilibrium data were
evaluated by using Ultraspin.
Determination of Peptide Phosphorylation Specificity
Phosphorylation motifs for ASK1 kinases were determined by using
a positional scanning peptide library approach essentially as de-
scribed before (Hutti et al., 2004). Reactions were carried out in multi-
well plates in 50 mM HEPES (pH 7.4), 10 mMMgCl2, 1 mM DTT, 0.1%
Tween 20, 100 mM ATP (including 0.3 mCi/ml g-[33P]-ATP), 50 mM
peptide substrate, and 50 mg/ml unphosphorylated ASK1 for 2 hr at
30C. Peptide substrates had the general sequence YAXXXXX-S/T-
XXXXAGKK(biotin), where S/T represents an even mixture of serine
and threonine, K(biotin) is 3-(biotinamidocaproyl)lysine, and X is
a roughly equimolar mixture of the 17 amino acids excluding cysteine,
serine, and threonine. Each well contained a distinct peptide in which
one of the X positions was replaced with 1 of 22 residues (one of the
unmodified proteogenic amino acids exlcuding pSer and pThr). In ad-
dition, three additional wells were included that contained either no
peptide, the peptide YAXXXXX-S-XXXXAGKK(biotin), or the peptide
YAXXXXX-T-XXXXAGKK(biotin), to test phosphoacceptor residue
preference. At the end of the incubation time, aliquots of each reaction
were spotted onto streptavidin membrane, which was processed as
described by Hutti and coworkers (Hutti et al., 2004).
Phosphorylation Site Mapping
The protein was denatured by boiling, cysteine residues were reduc-
tively alkylated, and then a tryptic digest was performed overnight
(100:1 protein/enzyme ratio). The peptides were separated on aDionex
3000 nano-LC system with a C18 Pepmap column by using a water/
acetonitrile gradient with 0.1% formic acid and analyzed with a Bruker
HCT Ultra ion trap in MS/MS mode. Alternating fragmentation cycles
were performed in data-dependent MS/MS by using collision-induced
dissociation (CID) and electron transfer dissociation (ETD), the data
were submitted to Mascot searches (http://www.matrixscience.com/)
separately, and the information from the two alternative approaches
was combined.
Plasmid Construction for Transfection Studies
ASK1-WT and ASK1-T838 (human; T845 for murine) were described
previously (Zhang et al., 2005). ASK1 mutants (T813A and T842A)
were constructed by site-directed mutagenesis with a Quickchange
site-directed mutagenesis kit (Stratagene) according to the protocol
of the manufacturer. Transfection of 293T cells were performed by Lip-
ofectamine (Invitrogen). Luciferase activity followed by renilla activity
was measured twice in duplicate with a Berthold luminometer. All
data were normalized as relative luciferase light units/renilla unit.
Immunoblotting
Cell lysates were subjected to SDS-PAGE followed by immunoblot (IB)
with a specific antibody (e.g., anti-HA) followed by HRP-conjugated
anti-mouse secondary antibody. Protein was detected by chemilumi-
nescence with an ECL kit according to the instructions of the manufac-
turer (Amersham Life Science).226, October 2007 ª2007 Elsevier Ltd All rights reserved 1223
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Initial screens were set up with ASK1 kinase domain and several high-
affinity small-molecular inhibitors. Crystals appeared in several condi-
tions when 1 mM staurosporine was added to the protein. Screen con-
ditions that yielded crystals all contained 20%–25% PEG 4000 or PEG
6000, 0.2 M salt, and had a pH around 6.0 (buffered or unbuffered).
After optimisation, diffraction quality needle-like crystals were ob-
tained from 25% PEG3350, 0.17 M (NH4)2SO4, and 15% glycerol
with average dimensions 0.2 3 0.05 3 0.05 mm3 and were mounted
with a loop and flash frozen by plunging into liquid nitrogen. Datasets
were collected at the PXII beamline at the Swiss Light Source with
a MAR225 detector at 0.972 A˚.
Selenomethionine-labeled protein did not yield crystals using the
same crystallization condition, and initial screening was repeated.
Eventually, needle-like crystals were obtained from 18% PEG6000
and 0.1 M H3Cit/Na3Cit (pH 4.9). A SAD dataset was collected at the
PXII beamline at the SLS by using the selenium peak wavelength
(0.9789 A˚, determined from a fluoresence scan). Diffraction images
were processed with XDS (Kabsch, 2001) different scans were scaled
together with XSCALE (Kabsch, 2001). Data collection statistics are
shown in Table 1.
Structure Solution and Refinement
Although molecular replacement solutions could be obtained by
employing either an ensemble of most similar structures (29%–31%
sequence identity, including only theC-terminal domain) or a homology
model as searchmodel, refinement was unstable and diverged. Unfor-
tunately, the anomalous signal in the selenomethione-labeled protein
was too weak to result in structure solution on its own. Although sele-
nium positions could be located from the anomalous data with
SHELXD (Sheldrick et al., 2001), no interpretable map was obtained.
Initially, the homology model that was used in molecular replace-
ment of the unlabeled protein was used in Phaser (McCoy et al.,
2005), and a molecular replacement solution for the selenomethionine
crystal was obtained. This model was refined in refmac5 (Murshudov
et al., 1997), and phase restraints (phase probability distribution was
obtained by SHARP [La Fortelle and Bricogne, 1997] from Se positions
determined by SHELXD and expressed as Hendrickson-Lattman coef-
ficients) were vital for keeping refinement stable. After several rounds
of manual rebuilding, the model improved significantly and could be
used for molecular replacement of the native dataset. Phaser located
twomolecules in the asymmetric unit, revealing that solutions obtained
previously were incomplete and missing the second molecule. Multi-
crystal averaging, enabled by the fact that crystals from the unlabelled
and selenomethionine-labeled protein were nonisomorphous and had
a different cell and space group, was performed and resulted in a clear
electron density map that was manually traced. Refinement was com-
pleted in refmac5 and converged to an R/Rfree of 0.198/0.251. The
resulting model was deposited with the Protein Data Bank under
accession ID 2CLQ.
Supplemental Data
Supplemental Data include the melting profiles of the identified inhib-
itors (Figure S1) as well as the chemical structures (Table S1), charac-
terization of the autophosphorylation sites by mass spectroscopy
(Figure S2), quantified peptide array data (Table S2), and detailed de-
scription of interaction in the dimer interface (Table S3) and are avail-
able at http://www.structure.org/cgi/content/full/15/10/1215/DC1/.
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